Teva, Lundbeck drop oral Copaxone

TEVA and partner H. Lundbeck (CSE:LUN) discontinued development of an oral enteric coated formulation of multiple sclerosis (MS) drug Copaxone glatiramer. The decision was based on results from a fail...